Berkeley Lights Scoops Up IsoPlexis, Creating A Premier Functional Cell Biology Company

  • Berkeley Lights Inc (NASDAQ: BLI) has agreed to acquire IsoPlexis Corp (NASDAQ: ISO) in an all-stock transaction valued at $57.8 million.

  • The combined company, which will be named PhenomeX, will be an operating cell biology company that provides live cell biology research tools.

  • Under the terms of the agreement, IsoPlexis shareholders will receive 0.612 shares of Berkeley Lights stock for each IsoPlexis share they hold.

  • Following the close of the transaction, Berkeley Lights shareholders will own approximately 75.2% of the combined company, and IsoPlexis shareholders will own approximately 24.8%.

  • Siddhartha Kadia will serve as CEO and a member of the combined company’s Board of Directors; and

  • Sean Mackay is expected to be appointed chief product officer of the combined company.

  • The combined company anticipates delivering cost synergies of approximately $70 million annualized by 2024. The new company is expected to generate a positive operating cash flow of $150 million in revenue by 2024.

  • The transaction is expected to close in the first quarter of 2023.

  • Price Action: ISO stock is up 62.30% at $1.12 during the premarket session on the last check Thursday. BLI stock is down 8.79% at $2.18.

See more from Benzinga

Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Source: https://finance.yahoo.com/news/berkeley-lights-scoops-isoplexis-creating-123747395.html